Liver Fibrosis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 193 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Liver Fibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H1 2016', provides an overview of the Liver Fibrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
- The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Liver Fibrosis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Fibrosis Overview 9
Therapeutics Development 10
Pipeline Products for Liver Fibrosis - Overview 10
Pipeline Products for Liver Fibrosis - Comparative Analysis 11
Liver Fibrosis - Therapeutics under Development by Companies 12
Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes 15
Liver Fibrosis - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Liver Fibrosis - Products under Development by Companies 18
Liver Fibrosis - Products under Investigation by Universities/Institutes 21
Liver Fibrosis - Companies Involved in Therapeutics Development 22
Advinus Therapeutics Ltd. 22
AiCuris GmbH & Co. KG 23
Akarna Therapeutics Ltd. 24
Angion Biomedica Corp. 25
Asubio Pharma Co., Ltd. 26
Bioneer Corporation 27
BiOrion Technologies B.V. 28
Bird Rock Bio, Inc. 29
Bristol-Myers Squibb Company 30
Celgene Corporation 31
Dicerna Pharmaceuticals, Inc. 32
Digna Biotech, S.L. 33
Dr. Falk Pharma GmbH 34
Dynavax Technologies Corporation 35
Evotec AG 36
FibroGen, Inc. 37
Galectin Therapeutics, Inc. 38
Genfit SA 39
Gilead Sciences, Inc. 40
GNI Group Ltd. 41
HEC Pharm Co., Ltd. 42
Immuron Limited 43
Intercept Pharmaceuticals, Inc. 44
INVENT Pharmaceuticals, Inc. 45
Isarna Therapeutics GmbH 46
KineMed, Inc. 47
LG Life Science LTD. 48
Nitto Denko Corporation 49
Pfizer Inc. 50
Pharmaxis Limited 51
Promedior, Inc. 52
Promethera Biosciences S.A. 53
ProMetic Life Sciences Inc. 54
RXi Pharmaceuticals Corporation 55
SciFluor Life Sciences, LLC 56
TCM Biotech International Corp 57
Vascular Biogenics Ltd. 58
Virobay Inc. 59
XTuit Pharmaceuticals, Inc. 60
Liver Fibrosis - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
AIC-649 - Drug Profile 73
ANG-3070 - Drug Profile 74
ANG-3281 - Drug Profile 75
ANG-4011 - Drug Profile 76
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 77
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 78
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 79
ASB-14780 - Drug Profile 80
BMS-986171 - Drug Profile 81
BOT-162 - Drug Profile 82
CC-539 - Drug Profile 83
CIGB-500 - Drug Profile 84
CPI-43132 - Drug Profile 85
CT-140 - Drug Profile 86
DB-036 - Drug Profile 87
Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 88
Drugs for Tissue Fibrosis - Drug Profile 89
DV-1079 - Drug Profile 90
F-351 - Drug Profile 92
FG-3019 - Drug Profile 94
GM-CT-01 - Drug Profile 96
GRMD-02 - Drug Profile 99
HEC-00000585 - Drug Profile 102
HepaStem - Drug Profile 103
IMM-124E - Drug Profile 105
INT-767 - Drug Profile 107
INV-340 - Drug Profile 109
ISTH-0047 - Drug Profile 110
KW-0 - Drug Profile 112
LC-280126 - Drug Profile 113
melittin - Drug Profile 115
MOR-8457 - Drug Profile 116
ND-L02s0201 - Drug Profile 117
norursodeoxycholic acid - Drug Profile 119
noscapine - Drug Profile 121
PBI-4050 - Drug Profile 122
PRM-151 - Drug Profile 124
PXS-5033A - Drug Profile 126
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 127
RXI-209 - Drug Profile 128
RYI-018 - Drug Profile 129
selonsertib - Drug Profile 130
selonsertib + simtuzumab - Drug Profile 131
Small Molecule for Liver Fibrosis - Drug Profile 132
Small Molecule for Liver Fibrosis - Drug Profile 133
Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile 134
Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 135
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 136
Small Molecules for Fibrosis - Drug Profile 137
Small Molecules for Hepatic Fibrosis - Drug Profile 138
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 139
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 140
TCM-808FB - Drug Profile 141
TGFTX-4 - Drug Profile 142
VB-201 - Drug Profile 143
VBY-376 - Drug Profile 145
VBY-825 - Drug Profile 146
Liver Fibrosis - Recent Pipeline Updates 147
Liver Fibrosis - Dormant Projects 177
Liver Fibrosis - Discontinued Products 180
Liver Fibrosis - Product Development Milestones 181
Featured News & Press Releases 181
Appendix 188
Methodology 188
Coverage 188
Secondary Research 188
Primary Research 188
Expert Panel Validation 188
Contact Us 188
Disclaimer 189

List of Tables

Number of Products under Development for Liver Fibrosis, H1 2016 14
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Development by Companies, H1 2016 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2016 25
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd., H1 2016 26
Liver Fibrosis - Pipeline by AiCuris GmbH & Co. KG, H1 2016 27
Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H1 2016 28
Liver Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016 29
Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H1 2016 30
Liver Fibrosis - Pipeline by Bioneer Corporation, H1 2016 31
Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016 32
Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H1 2016 33
Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2016 34
Liver Fibrosis - Pipeline by Celgene Corporation, H1 2016 35
Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 36
Liver Fibrosis - Pipeline by Digna Biotech, S.L., H1 2016 37
Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H1 2016 38
Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H1 2016 39
Liver Fibrosis - Pipeline by Evotec AG, H1 2016 40
Liver Fibrosis - Pipeline by FibroGen, Inc., H1 2016 41
Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 42
Liver Fibrosis - Pipeline by Genfit SA, H1 2016 43
Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H1 2016 44
Liver Fibrosis - Pipeline by GNI Group Ltd., H1 2016 45
Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H1 2016 46
Liver Fibrosis - Pipeline by Immuron Limited, H1 2016 47
Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 48
Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 49
Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016 50
Liver Fibrosis - Pipeline by KineMed, Inc., H1 2016 51
Liver Fibrosis - Pipeline by LG Life Science LTD., H1 2016 52
Liver Fibrosis - Pipeline by Nitto Denko Corporation, H1 2016 53
Liver Fibrosis - Pipeline by Pfizer Inc., H1 2016 54
Liver Fibrosis - Pipeline by Pharmaxis Limited, H1 2016 55
Liver Fibrosis - Pipeline by Promedior, Inc., H1 2016 56
Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H1 2016 57
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016 58
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H1 2016 59
Liver Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016 60
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H1 2016 61
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H1 2016 62
Liver Fibrosis - Pipeline by Virobay Inc., H1 2016 63
Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H1 2016 64
Assessment by Monotherapy Products, H1 2016 65
Assessment by Combination Products, H1 2016 66
Number of Products by Stage and Target, H1 2016 68
Number of Products by Stage and Mechanism of Action, H1 2016 71
Number of Products by Stage and Route of Administration, H1 2016 74
Number of Products by Stage and Molecule Type, H1 2016 76
Liver Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016 151
Liver Fibrosis - Dormant Projects, H1 2016 181
Liver Fibrosis - Dormant Projects (Contd..1), H1 2016 182
Liver Fibrosis - Dormant Projects (Contd..2), H1 2016 183
Liver Fibrosis - Discontinued Products, H1 2016 184